Inovio pharmaceuticals, inc. (INO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenue from Contract with Customer, Excluding Assessed Tax

2,609

4,111

6,335

7,469

31,782

30,481

36,766

37,410

33,373

42,220

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue under collaborative research and development arrangements

-

-

-

-

-

-

-

-

-

-

-

-

-

6,490

7,834

21,982

24,427

26,876

26,813

11,453

10,226

7,416

6,480

13,754

10,661

9,239

8,431

65

71

82

0

0

0

-

-

-

-

-

-

Revenue under collaborative research and development arrangements with affiliated entities

-

-

-

-

-

-

-

-

-

-

-

-

-

1,400

1,586

1,136

803

779

516

504

475

479

473

466

435

425

461

577

577

577

0

0

0

-

-

-

-

-

-

Revenue under collaborative research and development arrangements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

567

474

347

0

0

0

Revenue under collaborative research and development arrangements with affiliated entities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Revenue under collaborative research and development arrangements

-

-

-

-

-

-

-

-

-

-

-

-

-

6,490

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants and miscellaneous revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

27,136

23,140

21,313

18,284

12,916

9,762

2,792

2,564

2,560

2,785

3,164

3,273

3,802

3,969

3,587

3,231

3,458

3,980

5,825

7,804

9,227

8,803

7,308

0

0

0

Grants and miscellaneous revenue from affiliated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

340

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Miscellaneous revenue from affiliated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

35,368

32,789

44,432

43,515

40,572

37,093

14,750

13,265

10,456

9,739

17,385

14,369

13,467

12,862

4,230

3,880

4,118

4,616

6,399

8,383

9,795

9,439

7,936

0

0

0

Operating expenses:
Research and development

82,738

88,017

92,379

95,093

95,070

95,257

93,533

97,191

98,607

98,572

97,843

99,313

95,065

88,712

80,402

69,497

66,554

57,791

51,434

42,377

35,295

34,095

31,254

29,675

24,478

21,368

19,407

18,941

19,057

17,984

17,700

19,715

19,652

20,032

18,824

14,920

0

0

0

General and administrative

27,676

27,203

24,142

25,252

26,592

29,315

31,712

31,240

30,220

28,290

27,221

26,657

26,288

23,892

21,786

20,408

19,327

18,063

17,428

16,204

15,833

15,857

15,972

16,101

14,801

13,643

12,222

11,614

11,264

10,778

11,113

10,762

11,157

11,988

11,616

12,321

0

0

0

Gain (Loss) on Disposition of Intangible Assets

-

-

-

-

-

-

-

-

-

1,000

0

0

1,000

1,000

1,000

1,000

1,000

1,000

0

0

0

-

-

-

-

2,000

1,000

1,500

500

1,151

1,151

988

988

587

0

0

0

-

-

Total operating expenses

110,415

115,220

116,521

120,346

121,662

124,573

124,246

127,432

127,828

125,862

125,065

125,971

120,353

111,604

101,189

88,905

84,882

74,855

67,862

57,581

51,129

49,952

46,227

44,777

37,280

33,011

30,629

29,055

29,821

27,612

27,662

29,490

29,822

31,433

29,854

26,991

0

0

0

Loss from operations

-107,805

-111,108

-110,186

-112,877

-89,880

-94,091

-87,479

-90,022

-94,455

-83,642

-83,118

-74,128

-82,719

-76,235

-68,399

-44,473

-41,366

-34,283

-30,769

-42,830

-37,863

-39,495

-36,488

-27,391

-22,910

-19,544

-17,767

-24,825

-25,941

-23,493

-23,046

-23,090

-21,439

-21,638

-20,415

-19,054

0

0

0

Other income (expense):
Interest income

2,397

2,605

2,583

2,464

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

10,096

7,948

5,279

2,851

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income (expense), net

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Interest and other income, net

-

-

-

-

-

920

-

-

-

1,612

1,295

1,223

1,264

1,257

871

694

499

305

612

494

417

331

226

176

144

132

180

170

174

166

128

97

63

34

0

0

0

-

-

Change in fair value of common stock warrants

-

-

-

-

-

360

940

1,134

562

806

872

451

650

127

-807

-291

-227

177

611

-21

852

348

-5,848

-40,686

-44,710

-45,632

-36,530

-2,691

4,103

1,982

46

1,506

2,810

8,690

0

0

0

-

-

Change in fair value of derivative liability

-14,985

-1,763

2,551

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on investment in affiliated entities

10,841

-3,090

-4,702

-3,199

-5,119

-1,988

1,597

-5,255

-2,993

-6,982

-11,981

-7,104

-7,979

1,110

2,567

2,867

12,433

2,600

9,192

11,020

700

2,676

-2,085

-5

-579

-1,038

2,830

317

1,357

1,631

-1,658

-967

-2,582

-2,390

1,054

-3,700

0

0

0

Other income (expense), net

106

496

48

-214

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss before income tax benefit/(provision for income tax)

-124,592

-120,809

-115,536

-117,015

-93,968

-94,798

0

0

0

-

-

-

-

-

-

-

-

-31,200

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit/(provision for income taxes)

-194

-257

-169

-169

-62

2,169

0

0

0

-

-

-

-

-

-

-

-

-2,097

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-124,398

-120,551

-115,366

-116,845

-93,905

-96,967

-85,511

-94,630

-97,470

-88,205

0

0

0

-

-

-

-

-29,102

-18,563

-31,336

-35,892

-36,140

-44,195

-67,907

-68,056

-66,083

-51,287

-27,028

-20,306

-19,712

-24,529

-22,453

-21,146

-15,304

-11,230

-14,288

0

0

0

Net loss attributable to non-controlling interest

-1,717

-1,192

-707

-261

-69

0

0

0

0

-

-

-

-

-

-

-

-

84

83

82

-10

-18

-30

-42

-50

-55

-54

-51

-48

-44

-43

-47

-51

-51

-43

-26

0

0

0

Net loss attributable to non-controlling interest

-1,717

-1,192

-707

-261

-69

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss attributable to Inovio Pharmaceuticals, Inc.

-122,681

-119,359

-114,659

-116,584

-93,836

-96,967

0

0

0

-

-

-

-

-73,740

-65,458

-39,105

-26,648

-29,187

-18,646

-31,419

-35,882

-36,121

-44,164

-67,864

-68,005

-66,028

-51,232

-26,977

-20,258

-19,668

-24,486

-22,406

-21,095

-15,252

-11,186

-14,261

0

0

0

Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders
Basic and diluted (in dollars per share)

-0.26

-

-

-

-0.30

-

-

-

-0.36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-0.05

-0.03

-0.06

-0.04

-0.04

-0.02

-0.02

-0.01

-0.07

Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders
Basic ($ per share)

-

-0.38

-0.23

-0.30

-

-0.34

-0.27

-0.07

-

-0.24

-0.39

-0.13

-0.31

-0.35

-0.28

-0.26

-0.11

-0.25

0.08

-0.09

-0.17

-0.12

-0.12

-0.18

-0.20

-0.30

-0.64

-0.24

-0.23

-

-

-

-

-

-

-

-

-

-

Diluted ($ per share)

-

-0.38

-0.25

-0.30

-

-0.34

-0.27

-0.08

-

-0.24

-0.40

-0.13

-0.31

-0.36

-0.28

-0.26

-0.11

-0.25

0.07

-0.09

-0.18

-0.12

-0.12

-0.19

-0.20

-0.30

-0.64

-0.24

-0.23

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding
Weighted average number of common shares outstanding
Basic (shares)

-

-

-

-

-

-

92,423

91,153

-

-

-

-

-

-

-

-

-

-

-

-

-

60,610

60,392

60,232

55,159

52,127

47,989

44,988

39,038

-

-

-

-

-

-

-

-

-

-

Diluted (shares)

-

-

-

-

-

-

92,423

91,241

-

-

-

-

-

-

-

-

-

-

-

-

-

60,805

60,602

60,474

55,159

52,127

47,989

44,988

39,038

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

124,623

-

-

-

97,494

-

-

-

90,451

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

140,704

135,389

134,968

134,968

129,382

127,256

127,256

120,922

-

-

Weighted average number of common shares outstanding - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

102,928

102,811

Revenue under collaborative research and development arrangements
Revenue from Contract with Customer, Excluding Assessed Tax

937

3,636

5,825

7,020

31,342

29,860

34,897

33,435

25,407

28,407

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue under collaborative research and development arrangements with affiliated entities
Revenue from Contract with Customer, Excluding Assessed Tax

1,352

235

236

368

357

449

619

563

680

765

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Miscellaneous revenue, including from affiliated entities
Revenue from Contract with Customer, Excluding Assessed Tax

-

-

-

-

-

171

-

-

-

10,474

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants and miscellaneous revenue from affiliated entity
Revenue from Contract with Customer, Excluding Assessed Tax

-

-

-

-

-

-

-

-

-

2,572

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Miscellaneous revenue
Revenue from Contract with Customer, Excluding Assessed Tax

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-